Immunome's Varegacestat Shows Statistically Significant Efficacy Across All Key Endpoints
IMNM has more than doubled off its 52-week low of $7.96.
Summary
Immunome announced highly positive clinical trial results for its varegacestat treatment, demonstrating statistically significant improvements in both primary and all key secondary efficacy endpoints. This strong data provides significant validation following the company's submission of a New Drug Application (NDA) for varegacestat to the FDA on May 12th, as disclosed in an 8-K. Such comprehensive positive results are crucial for increasing the likelihood of regulatory approval and future commercial success for the drug.
At the time of this announcement, IMNM was trading at $21.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.96 to $27.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.